Loading
A phase 3 trial of Efbemalenograstim alfa in Breast cancer, run by EVIVE Biotechnology, completed.
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy is a phase 3 interventional study registered as NCT02872103 by EVIVE Biotechnology, with 122 participants recorded, started 2016-08 and reaching its primary completion in 2017-12-20. Interventions recorded: F-627, Placebo. Conditions recorded: Breast Cancer, Neutropenia.
Linked to the drug Efbemalenograstim alfa because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
122 enrolled.
SD 1.17; Figures from the ClinicalTrials.gov results section (first posted 2019-03-26), not from a publication · SD 1.35
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placeboprimary | F-627 | 83 | 1.3 days | - | - | link |
| Placebo | 39 | 3.9 days |
Shares Evive Biotech, Efbemalenograstim alfa, Male breast cancer, Breast cancer (all types) and the tag pipeline.
Shares Evive Biotech, Efbemalenograstim alfa, Breast cancer (all types) and the tag pipeline.
Shares Male breast cancer, Breast cancer (all types) and the tag pipeline.
Shares Male breast cancer, Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.